Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations

Journal of Hospital Infection

Volumn 60, Issue 3, 2005, Pages 191-200

  Wagenlehner, F M E ^a   Weidner, W ^b   Naber, K G ^a  

^a Urologische Klinik   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Antibiotic treatment of UTIs; Complicated UTIs; Emergence of antibiotic resistant uropathogens; Nosocomial UTIs

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOPENICILLIN; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFALEXIN; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFOTIAM; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFTAZIDIME; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ENOXACIN; ERTAPENEM; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; NORFLOXACIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; RIFAMPICIN; SULBACTAM; TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATION; BIOFILM; CROSS INFECTION; DIABETES MELLITUS; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG URINE LEVEL; ERADICATION THERAPY; EUROPE; GEOGRAPHIC DISTRIBUTION; GERMANY; GRAM STAINING; HEALTH SURVEY; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INFECTION COMPLICATION; INFECTION PREVENTION; KIDNEY CLEARANCE; KIDNEY FAILURE; LONG TERM CARE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; NORTH AMERICA; PATHOGENESIS; PREVALENCE; REVIEW; STRAIN DIFFERENCE; TREATMENT FAILURE; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS, URINARY; BACTERIURIA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS;

EID: 20344396843     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2004.12.017     Document Type: Review

References (37)

1. H. Rüden P. Gastmeier F.D. Daschner M. Schumacher Nosocomial and community-acquired infections in Germany. Summary of the results of the first national prevalence study (NIDEP) Infection 25 1997 199-202
2. P. Gastmeier G. Kampf N. Wischnewski Prevalence of nosocomial infections in representative German hospitals J Hosp Infect 38 1998 37-49
3. D.G. Maki P.A. Tambyah Engineering out the risk of infection with urinary catheters Emerg Infect Dis 7 2001 1-6
4. P.A. Tambyah V. Knasinski D.G. Maki The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care Infect Control Hosp Epidemiol 23 2002 27-31
5. A. Tambić T. Tambić N. Kučišec-Tepeš Prevalence and antibiotic sensitivity pattern variations of bacterial isolates in different seetings and different periods of ime Acta Med Croatica 50 1996 5-10
6. R.N. Jones K.C. Kugler M.A. Pfaller P.L. Winokur Characteristics of pathogens causing urinary tract infections in hospitals in North America: Results from the SENTRY Antimicrobial Surveillance Program, 1997 Diagn Microbiol Infect Dis 35 1999 55-63
7. D. Mathai R.N. Jones M.A. Pfaller Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: A report from the SENTRY Antimicrobial Surveillance Program (North America) Diagn Microbiol Infect Dis 40 2001 129-136
8. E. Bouza R. San Juan P. Muñoz A. Voss J. Kluytmans on Behalf of the Co-operative Group of the European Study Group on Nosocomial Infections (ESGNI) A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study) Clin Microbiol Infect 7 2001 523-531
9. T.E. Johansen Nosocomially acquired urinary tract infections in urology departments. Why an international prevalence study is needed in urology Int J Antimicrob Agents 23 Suppl. 1 2004 S30-S34
10. F.M.E. Wagenlehner S. Krčmery C. Held Epidemiological analysis of the spread of pathogens from a urological ward using genotypic, phenotypic and clinical parameters Int J Antimicrob Agents 19 2002 583-591
11. F.M.E. Wagenlehner A. Niemetz A. Dalhoff K.G. Naber Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000 Int J Antimicrob Agents 19 2002 557-564
12. R.N. Jones M.L. Beach M.A. Pfaller Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): More alike than different! Diagn Microbiol Infect Dis 41 2001 161-163
13. DIN-Taschenbuch 222. Medizinische und immunologie. Diagnostische verfahren. Deutsches Institut fur Normung e.v. Berlin, Wien and Zürich: Beuth Verlag GmbH 2000.
14. G.L. Drusano S.L. Preston C. Hardalo Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint Antimicrob Agents Chemother 45 2001 13-22
15. G. Kahlmeter An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: The ECO.SENS Project J Antimicrob Chemother 51 2003 69-76
16. K.A. Gordon R.N. Jones Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: Comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000) Diagn Microbiol Infect Dis 45 2003 295-301
17. J.W. Costerton Introduction to biofilm Int J Antimicrob Agents 11 1999 217-221
18. G. Reid Biofilms in infectious disease and on medical devices Int J Antimicrob Agents 22 2003 223-226
19. T. Goto Y. Nakame M. Nishida Y. Ohi Bacterial biofilms and catheters in experimental urinary tract infection Int J Antimicrob Agents 11 1999 227-231
20. T. Tsukamoto M. Matsukawa M. Sano Biofilm in complicated urinary tract infection Int J Antimicrob Agents 11 1999 233-236
21. F. Pea F. Pavan E. Di Qual Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia J Chemother 15 2003 563-567
22. G. Elhanan M. Sarhat R. Raz Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-aquired bacteriaemia due to urinary tract infection J Infect 35 1997 283-288
23. J.J. Schentag K.K. Gilliland J.A. Paladino What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 32 2001 39-46
24. J.J. Schentag Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit Crit Care Med 29 2001 100-107
25. M.A. Mulvey J.D. Schilling S.J. Hultgren Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection Infect Immun 69 2001 4572-4579
26. K.G. Naber Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 17 2001 331-341
27. D. Boy M. Well M. Kinzig-Schippers F. Sörgel D. Ankel-Fuchs K.G. Naber Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose Int J Antimicrob Agents 23 Suppl. 1 2004 6-16
28. K.G. Naber B. Bergman M.C. Bishop EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU) Eur Urol 40 2001 576-588
29. Vogel F, Naber KG, Wacha H, et al., Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Parenterale Antibiotika bei Erwachsenen. Chemother J 1999;8:2-49.
30. K.G. Naber K. Hollauer D. Kirchbauer W. Witte In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections Int J Antimicrob Agents 16 2000 239-243
31. K.G. Naber R. Fünfstück A. Hofstetter P. Brühl U. Hoyme Empfehlungen zur antimikrobiellen Therapie von Infektionen der Nieren und des Urogenitaltraktes bei Erwachsenen Chemother J 9 2000 193-199
32. S.E. Geerlings R.P. Stolk M.J.L. Camps Asymptomatic bacteriuria may be considered a complication in women with diabetes Diabetes Care 23 2000 744-749
33. K. Drlica A strategy for fighting antibiotic resistance ASM News 67 2001 27-33
34. R. Raz Asymptomatic bacteriuria. Clinical significance and management Int J Antimicrob Agents 22 Suppl. 2 2003 45-47
35. F.M.E. Wagenlehner A. Niemetz K.G. Naber Erregerspektrum und antibiotikaresistenz von erregern bei stationären urologischen patienten mit harnwegsinfektionen (1994-2001) und konsequenzen für die antibiotikatherapie Urologe [A] 43 2003 13-25
36. T.M. Hooton Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection Int J Antimicrob Agents 22 Suppl. 2 2003 65-72
37. K.G. Naber R. Fünfstück S. Gatermann U. Hoyme Infektionen der Nieren und des Urogenitaltraktes Chemother J 13 2004 78-84